HAVCR2 and melanoma: In addition, compared to control, ICBs, with or without guadecitabine, downmodulated the expression of TIM-3, an alternative immune checkpoint, particularly expressed on B16F10 cells (Fig. 3A), similarly to what found on human melanoma cells [43].